The Latest Breaking News from PTC

PTC saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 90 to 96.

The U.S. Food and Drug Administration approved on Monday PTC Therapeutics, Inc.’s (NASDAQ:PTCT) SEPHIENCE (sepiapterin) for children and adult patients with phenylketonuria (PKU).

PTC Inc. has underperformed its software peers over the past year, and analysts are somewhat optimistic about the stock’s prospects.

PTC has underperformed the broader market over the past year, yet analysts remain moderately optimistic about the stock’s prospects.

PTC is prepared to release its second-quarter results later this month, with analysts predicting a single-digit earnings drop.

Despite PTC Inc.’s recent underperformance relative to its broader sector, analysts remain highly optimistic about the stock’s prospects.

Although PTC has underperformed the broader market over the past year, analysts remain highly optimistic about its future potential.

As the robotics field progresses and enters more industries, robotics stocks are becoming increasingly promising investments. With AI-driven advancements accelerating growth, now could be an opportune time to tap into this booming sector with fundamentally sound stocks like PTC Inc. (PTC), UiPath (PATH), and FARO Technologies (FARO). Read more….

PTC is scheduled to release its fiscal first-quarter earnings by the end of this month, and analysts anticipate a decline in its EPS by lower-double digits.